DUBLIN--(BUSINESS WIRE)--The "Pemphigus Vulgaris (PV) - Market Insights, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the PV, historical and forecasted epidemiology as well as the PV market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The PV market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM PV market size from 2017 to 2030. The report also covers current PV treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities and assesses the underlying potential of the market.
Pemphigus Vulgaris (PV) Diagnosis
Generally, patients with unexplained chronic mucosal ulceration, particularly with bullous skin lesions, have been suspected of having PV. It is essential to differentiate PV from other bullous dermatoses. Two clinical findings that are specific for PV include the Nikolsky sign and Asboe-Hansen sign. The diagnosis of PV is confirmed by biopsy of lesion and surrounding (perilesional) normal skin. Immunofluorescence testing shows IgG autoantibodies against the keratinocyte's cell surface. Serum autoantibodies to desmoglein 1 and desmoglein 3 transmembrane glycoproteins can be identified via direct immunofluorescence, indirect immunofluorescence, and enzyme-linked immunosorbent assay (ELISA).
Pemphigus Vulgaris (PV) Treatment
There is currently no cure for the treatment of PV, but treatment can help keep the symptoms under control. The majority of the therapies aim to improve the symptoms associated with pemphigus by the reduction of serum autoantibodies, either directly or through generalized immune suppression. The goal of the initial phase of therapy is disease control that means preventing the formation of new blisters and starting the healing process of the existing blisters. This initial phase ends when there is no blister appearing for 2 weeks, and the existing lesions have been healed.
The first line of treatment during the initial phase of therapy is corticosteroids (prednisolone)., owing to their rapid effect (within days). Completed remission with minimal treatment needs months while complete treatment remission off treatment requires several months or years of therapy. Systemic corticosteroids can also be used in combination with immunosuppressive agents (Azathioprine, Mycophenolate mofetil, Rituximab), in the cases where there are expected complications of hypertension, diabetes mellitus, or osteoporosis due to prolonged use (>4 months) of the steroids.
The second line of treatment in the cases of contraindications to glucocorticosteroids or complications due to prolonged use consists of the combined or single use of immunosuppressants such as azathioprine, mycophenolate mofetil (MMF), dapsone, methotrexate, cyclophosphamide, and cyclosporine.
Other treatment options include intravenous immunoglobulins (IVIG), immunoadsorption, plasmapheresis, and extracorporeal photochemotherapy.
Pemphigus Vulgaris (PV) Epidemiology
The disease epidemiology covered in The report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of PV, Gender-specific Diagnosed Prevalent Population of PV, Severity-specific Diagnosed Prevalent Population of PV, and Age-specific Diagnosed Prevalent Population of PV scenario of PV in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
- The increasing geriatric population and rising prevalence of PV generates a large patient population in the 7MM. In 2017, the diagnosed prevalent population of PV in the 7MM was 41,217.
- The United States contributes the largest share with 13,526 cases in 2017 acquiring near about 32.81% of the totals 7MM share. On the other hand, EU5 and Japan account for 60.10% and 7.09% diagnosed prevalent population share respectively in 2017.
- A female predominance in PV is well established. However, the genetic and physiological basis for this gender bias is not well understood. In 2017, males and female contribute to 5,275 and 8,251 diagnosed prevalent cases in the US.
- The proprietary epidemiology model for PV estimates that out of the total diagnosed prevalent population of 13,526 cases in the US for PV in 2017, 5,814 cases are of mild, 3,678 cases are of moderate, and 4,034 accounted for severe cases, respectively.
- The majority of the PV cases were found in adults between 60-70 years of age. In 2017, 3,014 cases, 2,449 cases, were contributed by patients age 60-69 years, 70-79 years, and lowest cases observed in the age-group of 0-17 years (406 cases) in 2017, respectively in the US.
Scope of the Report
- The report covers the descriptive overview of PV, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
- Comprehensive insight has been provided into the PV epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for PV is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the PV market; historical and forecasted is included in The report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM PV market.
- The increasing prevalence of the disease along with promising emerging pipeline therapies will positively drive the PV market.
- The companies and academics are working to assess challenges and seek opportunities that could influence PV R&D.
- Major players are involved in developing therapies for PV. Launch of emerging therapies will significantly impact the PV market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
- Genentech/Roche Group
- Principia Biopharma
- Novartis Pharmaceuticals/MorphoSys
- Argenx BVBA
- Topas Therapeutics
- and many more
For more information about this report visit https://www.researchandmarkets.com/r/xfrgx0